Regulations for medical trials require consent to be reinstated every time there is a change to the specifications which is often administratively laborious. Returning customer, Dale Jessop and his business partner wanted to create a platform that would capture the consent of volunteers more efficiently during clinical trials in the hope of reducing time and labour costs.
The product was timely so the client chose to work with B13 Technology knowing we could scale up quickly and deliver a product which they had personally invested in.
B13 Technology’s solution
To help build the Consentify platform, we facilitated a direct developer resource for the client. The developers created an MVP from scratch using their expertise in the programming languages Ruby and Angular. From design to concept, the project took approximately 10 months to complete.
“B13 Technology, and especially Jon & Tom, are good people and for me that’s a prerequisite for doing business. A combination of tech expertise plus a thorough understanding of the healthcare industry and clinical trials made the team a natural fit for the project. B13 Technology were quick to understand the project's requirements and start development.
There are always unforeseen problems in every tech project but I knew from prior experience of working with the agency that they were approachable, receptive to feedback and we could work through any problems together.”
Dale Jessop • Founder of Aftesi Ltd and former CTO of Exco InTouch
The e-consent solution created a digital blueprint and accelerated the use of this technology in the healthcare sector. Rather than just focussing on the participant needs, the solution met the needs of medical authors, clinical research associates and site investigators as the regulations set by the FDA or MHRA. A consequence of this broader approach helps to improve the understanding of participants and consent rates within clinical trials.
On completion of the MVP, and just prior to launch, our client sold the app to one of the several interested parties within the pharma-tech sector.